Published in:
01-09-2004 | Original Article
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children
Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2004
Login to get accessAbstract
Purpose
To describe mesna excretion in children.
Patients and methods
We studied 14 children (aged 1–18 years) who received 1.8 g/m2 of ifosfamide per day for 5 days. For uroprotection, the children were given intravenous mesna (equal to 20% of the ifosfamide dose) followed by two oral doses (each equal to 40% of the ifosfamide dose). The concentrations of mesna and the metabolite dimesna were measured in urine samples collected on treatment days 1 and 5.
Results
Of 14 patients enrolled, 11 (aged 4–18 years) were evaluable. The profiles of mesna excretion rates were similar on days 1 and 5. Mesna excretion declined rapidly over 1–2 h after intravenous dosing. Increases in mesna excretion after oral dosing lagged by 2–4 h. About 21% of the mesna administered was excreted unchanged over 24 h on both days 1 and 5. The proportion excreted varied by severalfold between patients, but there was no association with age.
Conclusion
The profile of mesna excretion after intravenous and oral dosing in these children was similar to that in reported studies of ifosfamide-treated adults.